Health Care·Life Sciences Tools & Services·$6.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.30 | N/A | +328.57% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.30 | N/A | +328.57% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management conveyed a positive outlook regarding their earnings performance. However, they did not provide specific guidance for future quarters.
Management expressed satisfaction with the EPS performance despite not providing revenue figures.
They highlighted ongoing operational improvements as a key factor in their success.
Repligen Corp's strong EPS performance, significantly exceeding expectations, led to a positive stock reaction, with shares rising by 5%. The lack of revenue data leaves some uncertainty, but management's comments suggest confidence in ongoing operational improvements. Investors may view the EPS beat as a sign of the company's potential for growth moving forward.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
ABM INDS INC
Mar 4, 2013